Receptor binding of oxytocin and vasopressin antagonists
and inhibitory effects in isolated myometrium from preterm and term pregnant women.
Key agents in development are primarily focused on targeting cardiovascular neurohormonal pathways, such as arginine vasopressin antagonists
(which include Otsuka's Tolvaptan) and renin-angiotensin aldosterone system modulators (which include Novartis's Aliskiren).
as aquaretic agents for the treatment of hyponatremia.
("aquaretics") slow the production of vasopressin, a hormone that causes the kidneys to hold water.
Renal microvascular effects of vasopressin and vasopressin antagonists
. Am J Physiol 1989; 256:F274-F278.
Turning to the vasopressin antagonists, Mihai Gheorghiade, M.D., said these agents address two major underserved aspects of heart failure: congestion and hyponatremia.
Three investigational vasopressin antagonists are being developed for patients with both heart failure and hyponatremia.
Turning to vasopressin antagonists
, Mihai Gheorghiade, M.D., said these agents address two major underserved aspects of heart failure: congestion and hyponatremia.
* Vasopressin antagonists. Nicknamed "super diuretics," these drugs cause profound diuresis without disrupting electrolytes.
Two vasopressin antagonists, or "vaptans," have been tested in clinical trials: conivaptan and tolvaptan.